Mansfield A S, Tafur A J, Wang C E, Kourelis T V, Wysokinska E M, Yang P
Department of Oncology, Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Department of Medicine, Division of Cardiology - Vascular Medicine Program, NorthShore University Health System, Evanston, IL, USA.
J Thromb Haemost. 2016 Sep;14(9):1773-8. doi: 10.1111/jth.13378. Epub 2016 Sep 9.
Essentials Venous thromboembolism (VTE) prevention strategies require effective risk assessment models. We sought to validate the Khorana Risk Score (KRS) in patients with lung cancer. A high KRS was not predictive of VTE but was independently associated with all-cause mortality. Our findings stress the need for a lung cancer-specific VTE risk assessment model.
Objectives Lung cancer is strongly associated with venous thromboembolism (VTE), but primary prevention against VTE is not a validated management strategy. Risk assessment models will be necessary for efficient implementation of preventative strategies. Materials and methods Utilizing a prospectively collected lung cancer database, we aimed to validate the Khorana Risk Score (KRS) in the prediction of VTE among patients with lung cancer. VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risk models. Mortality prediction was evaluated as a secondary outcome. Results We included 719 patients in our review. The patients were predominantly older men with non-small cell lung cancer and 40% had metastatic disease at inception. The median follow-up was 15.2 months. There were 83 VTEs (11.5%) and 568 (78.8%) patients died. A high KRS (cumulative incidence, 12.4%; 95% confidence interval [CI], 6.4-20.5%) was not associated with VTE compared with an intermediate score (cumulative incidence, 12.1%; 95% confidence interval, 9.5-15.0%) in both univariate and multivariable analyses. However, a high KRS was a predictor of mortality (hazard ratio, 1.7; 95% CI, 1.4-2.2). Conclusions Among patients with lung cancer, the KRS did not stratify the patients at the highest risk of VTE. Improved risk stratification methods are needed for this group of patients prior to implementing a primary prevention strategy.
静脉血栓栓塞症(VTE)预防策略需要有效的风险评估模型。我们试图在肺癌患者中验证Khorana风险评分(KRS)。高KRS并不能预测VTE,但与全因死亡率独立相关。我们的研究结果强调了需要一个针对肺癌的VTE风险评估模型。
目的 肺癌与静脉血栓栓塞症(VTE)密切相关,但针对VTE的一级预防并非经过验证的管理策略。风险评估模型对于有效实施预防策略至关重要。材料和方法 利用前瞻性收集的肺癌数据库,我们旨在验证Khorana风险评分(KRS)在预测肺癌患者VTE方面的作用。VTE事件由不知道临床预测评分计算情况的审阅者进行回顾性识别。使用具有竞争风险模型的累积发病率函数来检查KRS与VTE风险之间的关联。将死亡率预测作为次要结果进行评估。结果 我们的综述纳入了719名患者。患者主要为患有非小细胞肺癌的老年男性,40%在初始时患有转移性疾病。中位随访时间为15.2个月。有83例VTE(11.5%),568例(78.8%)患者死亡。在单变量和多变量分析中,与中等评分(累积发病率,12.1%;95%置信区间,9.5 - 15.0%)相比,高KRS(累积发病率,12.4%;95%置信区间[CI],6.4 - 20.5%)与VTE无关。然而,高KRS是死亡率的预测因素(风险比,1.7;95%CI,1.4 - 2.2)。结论 在肺癌患者中,KRS并未对VTE风险最高的患者进行分层。在实施一级预防策略之前,这组患者需要改进风险分层方法。